Mar. 12 at 7:37 PM
$LUCD We are approaching the 1 year anniversary of BC/BS NY coverage. I really thought that would be the first of many regional plans to fall in line. It hasn't happened.
It has to be frustrating for management because they can't control Moldx, and they can't control medical policy decisions made by insurance companies. So what can they control? Two things IMO:
1) They can control how much they target CMS patients. Because of the 1 year look back, they should get paid for every CMS test that they conduct now, so that's a huge deal. If they can manage 2000-3000 CMS tests in Q1, that's
$4-6M in revenue to be recognized later and also puts them that much closer to profitability once CMS coverage is in place. It's super critical, and the #1 thing I will be listening for during the upcoming call.
2) They could make some open market purchases. There would be nothing better for signaling to the market "hey, we got this, it's just a matter of time."
